Business
Resverlogix Announces Combined RVX-208 findings from SUSTAIN & ASSURE Phase 2b Trials
"RVX-208 treated patients have significant lower MACE events in high risk CVD patients" ...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\"RVX-208 treated patients have significant lower MACE events in high\n risk CVD patients\"\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, Jan. 15, 2014 /CNW/ - Resverlogix Corp. (TSX: RVX) today\n announced new information arising from its ongoing analysis of data\n from both the SUSTAIN and ASSURE trials in atherosclerotic patients\n with high risk for recurrent events. This analysis, performed by an\n independent firm focuses on the potential benefit of RVX-208, a first\n in class BET-inhibitor, to impact major adverse cardiac events (MACE)\n over a short time period of 6 months.\n\n\nWhen MACE data (n=499) from both SUSTAIN and ASSURE trials were\n combined, it demonstrated that treatment with RVX-208 lead to a\n significant reduction in MACE.  RVX-208 treated patients (n=331), had\n less cumulative events of 6.74% vs. 15.09% (p=0.02) in the placebo\n treated group (n=168). Furthermore, in patients who had elevated CRP >\n 2.0mg/dL (n=283) the benefit of RVX-208 treatment of patients (n=179)\n appeared more striking with a cumulative event rate of 6.42% vs. 20.53%\n (p=0.007) in the placebo group (n=104).\n\n\n\"Analysis of the ASSURE and SUSTAIN data arising from similar\n atherosclerotic patients with high risk of recurrent events provides\n important MACE information,\" stated Donald McCaffrey President and\n Chief Executive Officer of Resverlogix. \"A reduction in MACE will be a\n critical factor for registration of RVX-208. This analysis provides\n important information that RVX-208 when used in high risk\n atherosclerosis patients improves the most central measurement of all,\n the reduction of MACE in back to back trials\" said Mr. McCaffrey.\n\n\n\"We are very excited to have this independent MACE analyses performed\n from the combined ASSURE and SUSTAIN trials to assess the RVX-208\n impact on death, non-fatal myocardial infarct, hospitalizations from\n cardiac events and percutaneous invasive procedures or\n revascularizations,\" stated Dr. Jan Johansson Senior Vice President of\n Medical Affairs at Resverlogix. \"This early data is valuable to have as\n it illustrates in a cumulative fashion that RVX-208 has the potential\n to really impact cardiac events in those patients who are at very high\n risk,\" Johansson added.\n\n\nAbout MACE\n\n\nMajor adverse cardiac events or MACE refers to adverse events c...